NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Receives Reiterated “Buy” Rating at Mizuho Securities
Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock following the FDA's Dermatologic and Ophthalmic Drug Advisory Committee vote in favor of Rhopressa. The committee’s decision regarded two key points: efficacy for reducing intraocular pressures (IOP) and efficacy outweighing safety risks. First, the committee voted 10-0 when asked if the clinical trials support Rhopressa's efficacy for reducing elevated IOP for patients with open-angle glaucoma or ocular hypertension. The second question posed to the committee asked if the identified safety risks were outweighed by the efficacy demonstrated…
